SCH-50971
Pharmaceutical compound
From Wikipedia, the free encyclopedia
SCH-50971 is a histamine H3 receptor agonist which was under development for the treatment of anxiety disorders, gastrointestinal disorders, and migraine but was never marketed.[2][3]
- None
| |
| Clinical data | |
|---|---|
| Other names | Sch-50971 |
| Routes of administration | Oral[1] |
| Drug class | Histamine H3 receptor agonist |
| ATC code |
|
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C8H13N3 |
| Molar mass | 151.213 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
The drug acts as a potent, selective, and high-affinity agonist of the histamine H3 receptor.[4][5] It has negligible affinity for the histamine H1 receptor and other assessed receptors.[4] The drug is also not a histamine H2 receptor antagonist.[4] It has greatly improved selectivity compared to the earlier selective histamine H3 receptor agonist (R)-α-methylhistamine.[4][5] The drug is orally active and shows anti-allergy effects, antimigraine effects, sedative and hypnotic effects, and hypolocomotion in animals.[6][7][1] In terms of chemical structure, it is a cyclized pyrrolidine derivative of histamine.[8][4]
Development
SCH-50971 was under development by Schering-Plough.[2] It reached the discovery or preclinical research stage of development.[3] The development of the drug was discontinued by 2001.[2] SCH-50971 was first described in the scientific literature by 1994.[9][10]
See also
- BP 2.94
- Cipralisant (GT-2331)
- GT-2203 (VUF-5296)
